Processing

Please wait...

Settings

Settings

Goto Application

1. WO2020107124 - METHODS OF MODULATING LEUKOCYTES ACTIVATION AND THROMBOCYTE CLEARANCE WITH INHIBITORS OF SPECIFIC NEURAMINIDASE ISOENZYMES

Publication Number WO/2020/107124
Publication Date 04.06.2020
International Application No. PCT/CA2019/051715
International Filing Date 29.11.2019
IPC
A61K 31/351 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
335having oxygen as the only ring hetero atom, e.g. fungichromin
35having six-membered rings with one oxygen as the only ring hetero atom
351not condensed with another ring
A61K 31/4192 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
41having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
41921,2,3-Triazoles
C07D 309/28 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
309Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
16having one double bond between ring members or between a ring member and a non-ring member
28with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
C07D 405/04 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
405Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
02containing two hetero rings
04directly linked by a ring-member-to-ring- member bond
CPC
A61K 31/351
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
335having oxygen as the only ring hetero atom, e.g. fungichromin
35having six-membered rings with one oxygen as the only ring hetero atom
351not condensed with another ring
A61K 31/4192
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
41having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
41921,2,3-Triazoles
C07D 309/28
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
309Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
16having one double bond between ring members or between a ring member and a non-ring member
28with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
C07D 309/30
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
309Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
16having one double bond between ring members or between a ring member and a non-ring member
28with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
30Oxygen atoms, e.g. delta-lactones
C07D 405/06
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
405Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
02containing two hetero rings
06linked by a carbon chain containing only aliphatic carbon atoms
Applicants
  • PCHEJETSKI, Alexey [CA]/[CA]
  • CAIRO, Christopher [CA]/[CA]
  • GUO, Tianlin [CA]/[CA]
  • HOWLADER, Amran [CA]/[CA]
  • DEMINA, Ekaterina [CA]/[CA]
Inventors
  • PCHEJETSKI, Alexey
  • CAIRO, Christopher
  • GUO, Tianlin
  • HOWLADER, Amran
  • DEMINA, Ekaterina
Agents
  • WHITE, Stephanie R.
  • FEUTLINSKE, Robert K.
  • MEE, Trevor R.
  • BEECH, Shannon L.
Priority Data
62/772,70429.11.2018US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) METHODS OF MODULATING LEUKOCYTES ACTIVATION AND THROMBOCYTE CLEARANCE WITH INHIBITORS OF SPECIFIC NEURAMINIDASE ISOENZYMES
(FR) MÉTHODES DE MODULATION DE L'ACTIVATION DES LEUCOCYTES ET DE LA CLAIRANCE DES THROMBOCYTES AVEC DES INHIBITEURS D'ISOENZYMES DE NEURAMINIDASE SPÉCIFIQUES
Abstract
(EN)
The present invention provides a method of modulating leukocytes activation (e.g., adhesion and/or transmigration and/or cytokine response) and a method of modulating thrombocyte clearance comprising administering to a subject in need thereof a specific inhibitor of neuraminidase 1 (neu1); neuraminidase 3 (neu3) or neuraminidase 4 (neu4); or a bispecific inhibitor of neu1, neu3 or neu4 of formula (I): (I) Also provided are pharmaceutical compositions comprising the inhibitor compound of formula (1), and uses thereof for modulating leukocytes activation or modulating thrombocyte clearance.
(FR)
La présente invention concerne une méthode de modulation de l'activation des leucocytes (par exemple l'adhésion et/ou la transmigration et/ou la réponse des cytokines) et une méthode de modulation de la clairance des thrombocytes comprenant l'administration à un sujet qui en a besoin d'un inhibiteur spécifique de la neuraminidase 1 (neu1); la neuraminidase 3 (neu3) ou la neuraminidase 4 (neu4); ou un inhibiteur bispécifique de neu1, neu3 ou neu4 de formule I : (I). L'invention concerne également des compositions pharmaceutiques comprenant le composé inhibiteur de formule 1, et leurs utilisations pour moduler l'activation des leucocytes ou moduler la clairance des thrombocytes.
Latest bibliographic data on file with the International Bureau